Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Aim. The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. Beside the prescription of some promising drugs as chloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab), in our patients with mild to moderate pneumonia due to SARS-CoV-2 we planned a randomize study to evaluate, respect the best available therapy (BAT), the use of autohemotherapy treatement with an oxygen/ozone (O3) gaseous mixture as adjuvant therapy. Design. Multicentric, randomized study. Participants. Clinical presentations are based upon clinical phenotypes identified by the Italian Society of Emergency and Urgency Medicine (SIMEU - Società Italiana di Medicina di Emergenza-Urgenza) and patients that meet criteria of phenotypes 2 to 4 were treat with best available therapy (BAT), and randomized to receive or not O3-autohemotherapy. Main outcome measures. The end-point were the time of respiratory improvement and earlier weaning from oxygen support: these parameters were included in the SIMEU clinical phenotypes classification.
Description: Evaluation of ABG paramethers the day after the last blood ozonization procedure (Day 3)
Measure: Time of respiratory improvement and earlier weaning from oxygen support Time: 3 daysDescription: Evaluation of ABG paramethers the one week after the last blood ozonization procedure (Day 10)
Measure: The time of respiratory improvement and earlier weaning from oxygen support Time: 10 daysDescription: Asse the lenghth of hospital stay in the two arms
Measure: Assessment of the length of hospitalization Time: up to 90 daysDescription: Asse the lenghth of ICU stay in the two arms
Measure: Assessment of the length of Intensive Care Unit (ICU) stay Time: up to 90 daysDescription: improving, worsening or stability of the chest imaging (chest CT, Chest XR and/or Point-of-Care Ultrasound) finding in the two arms
Measure: Improvment in chest imaging finding Time: 10 daysDescription: Evaluation of plasmatic cytochine (IL-6, lymphocyte typing for CD4, CD3, CD8, HLA-DR, CD45) response in the two arms
Measure: Improvment in cytokine release syndrome Time: 10 days